MBD2 serves as a viable target against pulmonary fibrosis by inhibiting macrophage M2 program.
Ontology highlight
ABSTRACT: Despite past extensive studies, the mechanisms underlying pulmonary fibrosis (PF) still remain poorly understood. Herein we demonstrated that lungs originated from different types of PF patients including coronavirus disease 2019, systemic sclerosis associated interstitial lung disease and idiopathic pulmonary fibrosis, and mice following bleomycin (BLM)-induced PF are characterized by the altered methyl-CpG-binding domain 2 (MBD2) expression in macrophages. Depletion of Mbd2 in macrophages protected mice against BLM-induced PF. Mbd2 deficiency significantly attenuated transforming growth factor ?1 (TGF-?1) production and reduced M2 macrophage accumulation in the lung following BLM induction. Mechanistically, Mbd2 selectively bound to the Ship promoter in macrophages, by which it repressed Ship expression and enhanced PI3K/Akt signaling to promote macrophage M2 program. Therefore, intratracheal administration of liposomes loaded with Mbd2 siRNA protected mice from BLM-induced lung injuries and fibrosis. Together, our data support that MBD2 could be a viable target against pulmonary fibrosis in clinical settings.
SUBMITTER: Wang Y
PROVIDER: S-EPMC7775789 | biostudies-literature | 2020 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA